Genitourinary Cancer

Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.

A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.

Although much remains unknown about the impact of COVID-19 on people with cancer, the impact on screening is becoming clearer.

Current and extended durations of non-aspirin use appeared associated with an increased risk for fatal renal cell carcinoma, according to study results.

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

Elizabeth Plimack, MD, MS, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, has been appointed the center’s deputy director.

In a research collaboration with Mayo Clinic, nanomedical company NaNotics LLC plans to develop and assess a novel subtractive nanoparticle for use in cancer treatment.

The FDA granted fast track designation to ALLO-316, an investigational chimeric antigen receptor T-cell therapy, for the treatment of adults with advanced or metastatic clear cell renal cell carcinoma.

Black Medicare beneficiaries who underwent elective cancer surgery had higher rates of mortality than their white counterparts, irrespective of neighborhood deprivation or dual eligibility status, according to study results.

Patients with urothelial carcinoma who experienced an immune-related adverse event following checkpoint blockade had significantly improved clinical outcomes, according to a poster presented at ASCO Genitourinary Cancers Symposium.